ライフサイエンスコーパス: BNCT

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 Thirty days after BNCT, mice bearing TK1(+) L929 tumors had a 15x reductio

2 gliomas, which had received i.t. BSD-EGF and BNCT, had a MST of 45 +/- 5 days compared with 33 +/- 2

3 of the distribution of a clinically approved BNCT drug.

4 ty and similar or even superior potential as BNCT agents compared with different classes of 3CTAs.

5 efficacy of binary cancer therapies such as BNCT and PDT depends critically on the subcellular local

6 n surgically removed malignant tissue before BNCT.

7 fluence was the limiting factor controlling BNCT efficacy in this study.

8 For BNCT experiments, tumor-bearing mice were irradiated 54

9 of high and low molecular weight agents for BNCT.

10 o not appear to be suitable boron agents for BNCT.

11 These results are important for BNCT, because clinical protocols using a 2-h infusion ha

12 make boronated aptamers as therapeutics for BNCT.

13 d to simulate a continuous infusion used for BNCT therapy.

14 n of tumor growth was observed in mice given BNCT vs. control mice (only 424% increase in tumor volum

15 ta are the first to show in vivo efficacy of BNCT using a high molecular weight boronated bioconjugat

16 potentially enhance the therapeutic ratio of BNCT by >25%.

17 rticular significance for clinical trials of BNCT for human glioblastoma multiforme using the drug BP

18 , it was possible to extend the follow-up of BNCT treatment groups to 16 wk after the first treatment

19 prove valuable for patient selection and pre-BNCT treatment planning.

20 of the biodistribution of BPA-Fr enables pre-BNCT calculation of expected tissue dosimetry for a sele

21 human glioblastoma tissue obtained from pre-BNCT surgical biopsy.

22 Once-repeated BNCT treatment with readministration of liposomes at an

23 Based on these favorable results, BNCT studies were then initiated in rats bearing intrace

24 On the basis of these results, BNCT was initiated at the Brookhaven National Laboratory

25 Successful BNCT depends on knowledge of the distribution of boron-c

26 unds promising boron delivery agents for the BNCT of brain tumors.

27 pplication of boron neutron capture therapy (BNCT) following liposomal delivery of a (10)B-enriched p

28 Success of boron neutron capture therapy (BNCT) is dependent on cellular and molecular targeting o

29 Boron neutron capture therapy (BNCT) is dependent on the selective accumulation of boro

30 pplication of boron neutron capture therapy (BNCT) mediated by liposomes containing (10)B-enriched po

31 d N5-2OH, for boron neutron capture therapy (BNCT) of brain tumors using the RG2 rat glioma model.

32 Boron neutron capture therapy (BNCT) using 4-[10B]boronophenylalanine-fructose (BPA-Fr)

33 Boron neutron capture therapy (BNCT), a binary treatment modality that can potentially

34 Boron neutron capture therapy (BNCT), an experimental treatment for certain cancers, de

35 ry agents for boron neutron capture therapy (BNCT).

36 ) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and mela

37 earing mice at 2-hour intervals, after which BNCT was carried out at the Massachusetts Institute of T

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。